胶质母细胞瘤是侵袭性脑肿瘤，中位生存期仍不到22个月。FDA批准的ALS药物Edaravone能抑制iNOS信号，而iNOS信号是脑肿瘤干细胞的关键调节因子。基于此，加拿大研究人员发现Edaravone在临床前模型的治疗延迟了胶质母细胞瘤的发生，并延长临床前模型的寿命 ...

Glioblastomas are aggressive brain tumors with a median survival time of less than 22 months despite standard therapy including surgery, irradiation, and chemotherapy. It has become clear in ...

Here's what the uOttawa-led team found: The drug edaravone (brand name Radicava) inhibits the self-renewal and proliferation of brain tumour stem cells so repurposing the drug may prove to be a ...

Longboard has commenced the Phase III DEEp OCEAN Study of bexicaserin for treating seizures linked to DEEs in two years and ...

An old drug could bring new hope for people suffering from the most common, and deadly, primary brain tumour in adults.

2023年，美国食品药品监督管理局(FDA)药品评价研究中心(CDER)共批准了55种新药（38个化药和17个生物药），批准数量远高于1993年以来的历史平均水平 ...

Oct 24th 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that a new clinical study with major clinical findings ...

Here’s what the uOttawa-led team found: The drug edaravone (brand name Radicava) inhibits the self-renewal and proliferation of brain tumour stem cells so repurposing the drug may prove to be a ...

Here's what the uOttawa-led team found: The drug edaravone (brand name Radicava) inhibits the self-renewal and proliferation of brain tumor stem cells so repurposing the drug may prove to be a ...

In an effort to rapidly identify new treatments effective against BTSCs, a team of researchers from the University of Ottawa, Canada, tested Edaravone, an FDA-approved drug, for its efficacy ...

NANJING, China, Oct. 25, 2024 /PRNewswire/ -- On October 24, 2024, TASTE-2, a Chinese innovative stroke drug study led by ...

The only ALS medications approved by the US Food and Drug Administration are Rilutek (riluzole), which extends the time to death by only several months, and Radicava (edaravone), which slows the ...